Daniel Brennan
Stock Analyst at TD Cowen
(1.76)
# 3,390
Out of 5,102 analysts
20
Total ratings
33.33%
Success rate
4.7%
Average return
Main Sectors:
Stocks Rated by Daniel Brennan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QTRX Quanterix | Maintains: Hold | $14 → $16 | $7.55 | +111.92% | 2 | Nov 13, 2024 | |
| LAB Standard BioTools | Maintains: Buy | $2.75 → $2.5 | $1.48 | +68.92% | 3 | Oct 31, 2024 | |
| AVTR Avantor | Maintains: Buy | $30 → $29 | $11.47 | +152.83% | 5 | Oct 8, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Buy | $12 → $2.5 | $2.17 | +15.21% | 2 | Apr 17, 2024 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $613 → $670 | $578.90 | +15.74% | 1 | Feb 2, 2023 | |
| CRL Charles River Laboratories International | Upgrades: Buy | $177 → $200 | $194.43 | +2.86% | 2 | May 13, 2020 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $755 → $770 | $1,421.58 | -45.83% | 2 | May 8, 2020 | |
| EXAS Exact Sciences | Maintains: Buy | $135 → $115 | $101.36 | +13.46% | 3 | Apr 28, 2020 |
Quanterix
Nov 13, 2024
Maintains: Hold
Price Target: $14 → $16
Current: $7.55
Upside: +111.92%
Standard BioTools
Oct 31, 2024
Maintains: Buy
Price Target: $2.75 → $2.5
Current: $1.48
Upside: +68.92%
Avantor
Oct 8, 2024
Maintains: Buy
Price Target: $30 → $29
Current: $11.47
Upside: +152.83%
Pacific Biosciences of California
Apr 17, 2024
Maintains: Buy
Price Target: $12 → $2.5
Current: $2.17
Upside: +15.21%
Thermo Fisher Scientific
Feb 2, 2023
Maintains: Overweight
Price Target: $613 → $670
Current: $578.90
Upside: +15.74%
Charles River Laboratories International
May 13, 2020
Upgrades: Buy
Price Target: $177 → $200
Current: $194.43
Upside: +2.86%
Mettler-Toledo International
May 8, 2020
Maintains: Neutral
Price Target: $755 → $770
Current: $1,421.58
Upside: -45.83%
Exact Sciences
Apr 28, 2020
Maintains: Buy
Price Target: $135 → $115
Current: $101.36
Upside: +13.46%